FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to CD19 specific polypeptide of chimeric antigen receptor (CAR) encoded by DNA sequence with SEC ID NO:5, 1-1485 SEQ ID NO:5 nucleotides or 67-1485 SEQ ID NO:5 nucleotides; it can be used in medicine.
EFFECT: invention allows for obtaining T-cells targeted to CD19, which can be used for the effective therapy of CD19+ malignant neoplasms.
17 cl, 42 dwg, 2 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
CELL | 2015 |
|
RU2768019C2 |
CHIMERIC ANTIGEN RECEPTORS TO MYELOMA KAPPA ANTIGEN AND VERSIONS OF THEIR APPLICATION | 2016 |
|
RU2743188C2 |
TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
CHIMERIC ANTIGENIC RECEPTORS TO CD22 | 2012 |
|
RU2644243C2 |
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
CHIMERIC ANTIGEN RECEPTOR | 2016 |
|
RU2752880C2 |
Authors
Dates
2021-08-24—Published
2015-02-16—Filed